News

VI Partners and High-Tech Gründerfonds also participated in the round which will help progress Amal’s cancer vaccines. Amal Therapeutics is a Swiss biotech company developing and progressing therapeutic

A team from Purdue University and the National Institutes of Health used cryo-electron microscropy to create the picture of a mature Zika virus particle. The process included freezing

The company said its decision was not based on any emerging safety concerns from the phase 3 clinical trials with fulranumab. Janssen Pharmaceuticals is terminating its licensing deal

"FDA’s approval of Defitelio underscores the importance of Defitelio to children and adults as the first and only proven treatment for this rare and often deadly complication of

The new pre-clinical studies demonstrated both a statistically significant reduction of inflammation (65% decrease in F4/80, and 80% decrease in CD64), as well as a statically significant effect

The local ethics committee, responsible for oversight and allowance of the trial, granted this approval, so the trial can now move forward. Cellceutix is now awaiting the country’s

The FDA has established September 15, 2016 as the Prescription Drug User Fee Act (PDUFA) action date. "This filing is another important step toward our goal of bringing

The deal expands the ongoing life sciences software and cloud-hosting services CSC is delivering to Tokyo-based Eisai’s US pharmaceutical subsidiary until December 2019. CSC has been providing regulatory

Opdivo is currently approved to treat various types of melanoma, lung cancer and kidney cancer. The data supporting the type II variation application was generated in the phase